This invention relates to novel compounds having the structural formula I below:
and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.
This invention relates to novel compounds having the structural formula I below:
and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.
[EN] AMINO-IMIDAZOLONES AND THEIR USE AS A MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT, ALZHEIMER DISEASE, NEURODEGENERATION AND DEMENTIA<br/>[FR] NOUVEAUX COMPOSÉS 317
申请人:ASTRAZENECA AB
公开号:WO2007145568A9
公开(公告)日:2008-12-11
[EN] This invention relates to novel compounds having the structural formula I below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia. [FR] La présente invention concerne de nouveaux composés répondant à la formule structurelle ci-après : et leurs sels pharmaceutiquement acceptables, compositions et procédés d'utilisation. Ces nouveaux composés permettent le traitement ou la prophylaxie d'une déficience cognitive, de la maladie d'Alzheimer, d'une neurodégénérescence et d'une démence.
[EN] AMINO-IMIDAZOLINES AND THEIR USE AS A MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT. ALZHEIMER DISEASE, NEURODEGENERATION AND DEMENTIA<br/>[FR] NOUVEAUX COMPOSÉS 317
申请人:ASTRAZENECA AB
公开号:WO2007145568A1
公开(公告)日:2007-12-21
[EN] This invention relates to novel compounds having the structural formula I below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia. [FR] La présente invention concerne de nouveaux composés répondant à la formule structurelle ci-après : et leurs sels pharmaceutiquement acceptables, compositions et procédés d'utilisation. Ces nouveaux composés permettent le traitement ou la prophylaxie d'une déficience cognitive, de la maladie d'Alzheimer, d'une neurodégénérescence et d'une démence.